# Molecular Express, Inc.: contracts, NIH (November 2026)

Registers read on November 19, 2026.

Molecular Express, Inc. (California) appears in 2 public registers SpecStream reads: 3 federal contract awards and 10 NIH and NSF awards; the newest record is dated July 16, 2026, and the registers were read on November 19, 2026.

SpecStream is the live web data engine for teams and agents. This page joins the public registers SpecStream already reads for one company.

- Registers: 2
- Newest record: July 16, 2026
- State: California

## Federal contract awards (USAspending)

3 federal contract awards, newest July 16, 2026.

- UEI: R1JMHFESEKD5
- Business size: Small Business
- Obligated: $5.0 million

| Record | Date | Detail | Source |
| --- | --- | --- | --- |
| [Department of Health and Human Services](https://specstream.ai/data/federal-awards/recipient/molecular-express-inc-r1jmhfesekd5) | September 1, 2024 | Definitive Contract, NAICS 541714; $3 million obligated | [usaspending.gov](https://www.usaspending.gov/award/CONT_AWD_75N93024C00017_7529_-NONE-_-NONE-/) |
| [Department of Health and Human Services](https://specstream.ai/data/federal-awards/recipient/molecular-express-inc-r1jmhfesekd5) | July 1, 2024 | Definitive Contract, NAICS 541715; $2 million obligated | [usaspending.gov](https://www.usaspending.gov/award/CONT_AWD_75N93024C00018_7529_-NONE-_-NONE-/) |
| [Department of Health and Human Services](https://specstream.ai/data/federal-awards/recipient/molecular-express-inc-r1jmhfesekd5) | September 30, 2023 | Definitive Contract, NAICS 541715; $0 obligated | [usaspending.gov](https://www.usaspending.gov/award/CONT_AWD_75N93023C00033_7529_-NONE-_-NONE-/) |

- [MOLECULAR EXPRESS, INC](https://specstream.ai/data/federal-awards/recipient/molecular-express-inc-r1jmhfesekd5)

## NIH and NSF research awards

10 NIH and NSF awards, newest September 1, 2024.

| Record | Date | Detail | Source |
| --- | --- | --- | --- |
| [NIH](https://specstream.ai/data/research-funding/organization/molecular-express-inc-r1jmhfesekd5) | September 1, 2024 | VESIVAX TLR7 FORMULA; $3 million | [reporter.nih.gov](https://reporter.nih.gov/project-details/11203954) |
| [NIH](https://specstream.ai/data/research-funding/organization/molecular-express-inc-r1jmhfesekd5) | July 1, 2024 | Design and Engineering of VesiVax HIV Immunogen Formulations; $2 million | [reporter.nih.gov](https://reporter.nih.gov/project-details/11172342) |
| [NIH](https://specstream.ai/data/research-funding/organization/molecular-express-inc-r1jmhfesekd5) | May 15, 2024 | Preclinical Development of a ME-1001, a Synthetic Lung Surfactant; $2 million | [reporter.nih.gov](https://reporter.nih.gov/project-details/11086104) |
| [NIH](https://specstream.ai/data/research-funding/organization/molecular-express-inc-r1jmhfesekd5) | September 30, 2023 | DEVELOPMENT OF VESIVAX CO-ADJUVANT FORMULATION OF 2E151 for flu vaccines; $599.9 thousand | [reporter.nih.gov](https://reporter.nih.gov/project-details/10933265) |
| [NIH](https://specstream.ai/data/research-funding/organization/molecular-express-inc-r1jmhfesekd5) | August 1, 2022 | Development of a VesiVax HIV Vaccine Formulation; $2.3 million | [reporter.nih.gov](https://reporter.nih.gov/project-details/10653678) |
| [NIH](https://specstream.ai/data/research-funding/organization/molecular-express-inc-r1jmhfesekd5) | July 8, 2022 | Niclosamide Formulations for the Treatment of Influenza Infections; $298.5 thousand | [reporter.nih.gov](https://reporter.nih.gov/project-details/10385194) |
| [NIH](https://specstream.ai/data/research-funding/organization/molecular-express-inc-r1jmhfesekd5) | July 1, 2022 | VesiVax HIVgp41e Vaccine Design; $300 thousand | [reporter.nih.gov](https://reporter.nih.gov/project-details/10667355) |
| [NIH](https://specstream.ai/data/research-funding/organization/molecular-express-inc-r1jmhfesekd5) | February 18, 2022 | VesiVax Vaccine Formulation Against Neisseria gonorrhoeae; $599.6 thousand | [reporter.nih.gov](https://reporter.nih.gov/project-details/10576383) |
| [NIH](https://specstream.ai/data/research-funding/organization/molecular-express-inc-r1jmhfesekd5) | August 1, 2021 | Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS; $2.2 million | [reporter.nih.gov](https://reporter.nih.gov/project-details/10672648) |
| [NIH](https://specstream.ai/data/research-funding/organization/molecular-express-inc-r1jmhfesekd5) | August 1, 2021 | DEVELOPMENT OF A VESIVAS IMMUNOSIMILAR FORMULATION; $569.8 thousand | [reporter.nih.gov](https://reporter.nih.gov/project-details/10470544) |

- [Molecular Express, Inc.](https://specstream.ai/data/research-funding/organization/molecular-express-inc-r1jmhfesekd5)

## How these records were matched

Records are joined when they carry the same SEC CIK, EIN or UEI, or when their legal names match word for word, legal form aside, at an address in the same state (California), and no register gives a second identifier, a second headquarters or a second filer of that name. Each record links to its own page and to the agency that published it.

Source: the registers named in each section. Public records of US federal and state agencies.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).
